drugset / Trial / NCT00522808
A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers
Phase 1/2
Terminated
36 enrolled
Arrow Therapeutics
DDS, Dundee · collabDavid Mutimer, Birmingham · collabEd Gane, ACS New Zealand · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purposes of this study are: * to determine the safety and tolerability of multiple doses of A-831 at various doses * to determine how multiple doses of A-831 are distributed through the bloodstream * to determine if A-831 reduces the amount of Hepatitis C virus in the blood
Timeline
- Start
- 2007-08
- Primary completion
- 2008-03
- Completion
- 2008-05
Outcome
Outcome not reported
Stopped: “Need for re-formulation”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | A-831 | Unknown | — | Oral |